Research Topics
| David E GerberSummaryAffiliation: University of Texas Southwestern Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Miscellaneous agents--cytotoxics and hormonal agentsDavid E Gerber
Department of Internal Medicine, Division of Hemtology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
J Thorac Oncol 7:S387-9. 2012..Hormonal agents included an aromatase inhibitor (anastrazole), an estrogen receptor antagonist (fulvestrant), and a selective androgen receptor modulator (GTx-024)...
Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenograftsDavid E Gerber
Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Mail Code 8852, Dallas, TX 75390 8852, USA
Mol Cancer Ther 11:2473-82. 2012..We conclude that stromal PDGFRα inhibition represents a means for enhancing control of lung cancer growth in some cases, independent of tumor cell PDGFRα expression...- A novel polymer gel for the delivery of local therapies to intracranial tumors: In vivo safety evaluationDavid E Gerber
Division of Hematology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
J Biomed Mater Res A 99:479-84. 2011..These results suggest that intracranial R-Gel is well tolerated. Therapeutic studies of chemotherapy-complexed R-Gel are underway... - Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapyDavid E Gerber
Department of Internal Medicine, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
J Thorac Oncol 6:365-71. 2011..We, therefore, determined the predictors and impact of second-line chemotherapy administration in a contemporary, diverse NSCLC population... - ALK inhibition for non-small cell lung cancer: from discovery to therapy in record timeDavid E Gerber
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, 75390, USA
Cancer Cell 18:548-51. 2010..Such therapy "targeted" at oncogenic proteins provides "personalized" medicine and prompts genome-wide mutation analysis of human tumors to find other therapeutic targets... - Cetuximab in combination therapy: from bench to clinicDavid E Gerber
Division of Hematology Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Mail Code 8852, Dallas, TX, 75390 8852, USA
Cancer Metastasis Rev 29:171-80. 2010..Combining cetuximab with radiation therapy extends survival in locally advanced head and neck cancer. As predictive biomarkers are identified, it may become possible to select patients most likely to benefit from such combinations... 
Targeted therapies: a new generation of cancer treatmentsDavid E Gerber
Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
Am Fam Physician 77:311-9. 2008..As more persons are diagnosed with cancer and as these patients live longer, primary care physicians will increasingly provide care for patients who have received targeted cancer therapy...- Recent advances in radiation therapyDavid E Gerber
Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
Am Fam Physician 78:1254-62. 2008..As more patients are diagnosed with cancer and as these patients live longer, primary care physicians will increasingly care for those who have received radiation therapy... - Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical centerJeffrey T Yorio
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
Clin Lung Cancer 13:448-57. 2012..To explore whether these differences are secondary to individual or institutional characteristics, we examined treatment selection and outcome in a diverse population treated at a single medical center... - Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse populationDrew W Rasco
Department of Internal Medicine Hematology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
J Thorac Oncol 5:1529-35. 2010..Therefore, we determined the use of chemotherapy in a contemporary, diverse NSCLC population encompassing all patient ages... - Consent timing and experience: modifiable factors that may influence interest in clinical researchDavid E Gerber
University of Texas Southwestern Medical Center, Dallas, TX
J Oncol Pract 8:91-6. 2012..However, few studies have examined factors related to the consent process. We therefore evaluated the impact of consent timing and experience on markers of patient interest in research... - A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesotheliomaJonathan E Dowell
Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
Lung Cancer 77:567-71. 2012..We evaluated the addition of bevacizumab to cisplatin and pemetrexed as first-line treatment in patients with advanced, unresectable MM... - Patient comprehension and attitudes toward maintenance chemotherapy for lung cancerDavid E Gerber
Department of Internal Medicine, Hematology Oncology, University of Texas Southwestern Medical Center, Dallas 75390 9066, USA
Patient Educ Couns 89:102-8. 2012..Maintenance chemotherapy is a recently approved approach to the treatment of advanced non-small cell lung cancer (NSCLC). We sought to gain insight into patients' perceptions of maintenance chemotherapy using qualitative methods... - Targeted therapies for lung cancer: clinical experience and novel agentsJill E Larsen
Hamon Center for Therapeutic Oncology Research, Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
Cancer J 17:512-27. 2011..Ongoing research efforts in these areas as well as a discussion of emerging targeted agents being evaluated in clinical trials are the subjects of this review... - The impact of consenter characteristics and experience on patient interest in clinical researchDrew W Rasco
Division of Hematology Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
Oncologist 14:468-75. 2009..However, the impact of nonphysician research personnel, who often consent patients for studies, is unclear. We therefore evaluated the association between consenter characteristics and subject interest in clinical research... - Lung cancer diagnostic and treatment intervals in the United States: a health care disparity?Jeffrey T Yorio
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
J Thorac Oncol 4:1322-30. 2009..We therefore studied the timing of lung cancer diagnosis and treatment at a U.S. medical center providing care to a diverse patient population within two different hospital systems... - Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumorsDavid E Gerber
Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Clin Cancer Res 17:6888-96. 2011..This phase I study assessed the safety and pharmacokinetics of bavituximab in patients with advanced solid tumors... - How have we diagnosed early-stage lung cancer without radiographic screening? A contemporary single-center experienceEvelyn O Taiwo
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
PLoS ONE 7:e52313. 2012..We therefore evaluated current patterns of early-stage lung cancer presentation... - Targeting the PI3K pathway for cancer therapyNavid Sadeghi
Division of Hematology and Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA
Future Med Chem 4:1153-69. 2012..This article provides an overview of our current knowledge of the PI3K pathway with an emphasis on its application in cancer treatment... - Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatmentPaul DeRose
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA
Immunotherapy 3:933-44. 2011..This article summarizes the preclinical development and clinical experience with bavituximab in non-small-cell lung cancer... - Emerging monoclonal antibody therapies for malignant gliomasDavid E Gerber
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Baltimore, Maryland, USA
Expert Opin Investig Drugs 16:477-94. 2007..Previous experience with mAbs in other malignancies may provide guidance for their use in the treatment of CNS malignancies...